Sarizotan
PreclinicalSmall molecule
EMD SeronoSarizotan is one of 8 small molecule programs targeting Tardive Dyskinesia. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Tardive Dyskinesia
#DrugCompanyPhaseTrials
1Ingrezza
Neurocrine BiosciencesApproved
Zyprexa
MMODAG GmbH
Approved
Risperdal
WWim Janssens
Approved
Barhemsys
Tibotec Pharmaceuticals, IrelandApproved
Abilify
OtsukaApproved
Reminyl
WWim Janssens
Approved
Austedo
TevaApproved
Sarizotan
EMD SeronoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Parkinson's Disease2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sarizotan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company